Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 22Neoplasm Metastasis 6Lung Neoplasms 5Neoplasms 4Carcinoma, Squamous Cell 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Brain Neoplasms 3NSCLC 2Head and Neck Neoplasms 2Glioblastoma 2Carcinoma 2Triple Negative Breast Neoplasms 1Thrombocytosis 1Skin Squamous Cell Cancer 1Rare Tumor 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Penile Neoplasms 1Pancreatic Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mouth Neoplasms 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

dacomitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Squamous Cell Cancer × dacomitinib × Clear all
NCT02268747 2016-07-04

Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Unknown
43 enrolled

Skin Squamous Cell Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡